Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

American Heart Journal

Volumn 170, Issue 4, 2015, Pages 675-682.e8

  Bansilal, Sameer ^a   Bloomgarden, Zachary ^a   Halperin, Jonathan L ^a   Hellkamp, Anne S ^b   Lokhnygina, Yuliya ^b   Patel, Manesh R ^b   Becker, Richard C ^c   Breithardt, Günter ^d   Hacke, Werner ^e   Hankey, Graeme J ^f   Nessel, Christopher C ^g   Singer, Daniel E ^h   Berkowitz, Scott D ⁱ   Piccini, Jonathan P ^b   Mahaffey, Kenneth W ^j   Fox, Keith A A ^k  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ BAYER CORPORATION   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CHADS2 SCORE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONVALVULAR ATRIAL FIBRILLATION; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SYSTEMIC DISEASE; SYSTEMIC EMBOLISM; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ATRIAL FIBRILLATION; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; TREATMENT OUTCOME; VITAMIN K;

EID: 84941939927     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.07.006     Document Type: Conference Paper

References (16)

1. Stroke Risk in Atrial Fibrillation Working Group Independent predictors of stroke in patients with atrial fibrillation: a systematic review Neurology 69 2007 546 554
2. B. Stegmayr, and K. Asplund Diabetes as a risk factor for stroke. A population perspective Diabetologia 38 1995 1061 1068
3. T.D. Wang, W.J. Chen, S.S. Su, and et al. Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism J Cardiovasc Electrophysiol 12 2001 877 884
4. I. Klem, C. Wehinger, B. Schneider, and et al. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up Diabetes Metab Res Rev 19 2003 320 328
5. Rocket AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347.e1
6. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
7. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and et al. A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
8. M. Brambatti, H. Darius, J. Oldgren, and et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial Int J Cardiol 196 2015 127 131
9. R.R. Huxley, A. Alonso, F.L. Lopez, and et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study Heart 98 2012 133 138
10. S. Dublin, N.L. Glazer, N.L. Smith, and et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation J Gen Intern Med 25 2010 853 858
11. R.R. Huxley, K.B. Filion, S. Konety, and et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation Am J Cardiol 108 2011 56 62
12. T.M. Davis, H. Millns, I.M. Stratton, and et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29 Arch Intern Med 159 1999 1097 1103
13. A.S. Go, E.M. Hylek, Y. Chang, and et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2692
14. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
15. R.G. Hart, L.A. Pearce, R. McBride, and et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators Stroke 30 1999 1223 1229
16. G.I. Varughese, J.V. Patel, J. Tomson, and et al. The prothrombotic risk of diabetes mellitus in atrial fibrillation and heart failure J Thromb Haemost 3 2005 2811 2813